Boston Scientific Begins Clinical Trial Enrollment for New Coronary Stent With Bioabsorbable Polymer and Everolimus Drug Coating

EVOLVE Trial to Evaluate Company's Fourth-Generation SYNERGY(TM) Drug-Eluting Coronary Stent

NATICK, Massachusetts, August 5, 2010 - Boston Scientific Corporation (NYSE: BSX) today announced the
start of patient enrollment in the EVOLVE clinical trial, which is designed
to assess the safety and performance of its fourth-generation SYNERGY(TM)
Coronary Stent. The first patient was enrolled by Ian Meredith, M.B.B.S.,
Ph.D., Professor and Director of MonashHeart, at Monash Medical Centre in
Melbourne, Australia.

The SYNERGY Stent uses a bioabsorbable PLGA polymer and
everolimus drug formulation to create a thin, uniform coating confined to the
outer surface of the stent. Once the drug has been delivered, the
bioabsorbable coating resorbs into the body, leaving behind only a bare-metal
stent. This technology is designed to provide the same degree of restenosis
reduction as a conventional drug-eluting stent while offering faster and more
complete vessel healing after stent implantation. The SYNERGY Stent features
the same proprietary platinum chromium alloy and innovative stent design used
in the PROMUS(R) Element(TM) Stent to enable thinner struts, increased
flexibility and a lower profile while improving radial strength, recoil and
visibility.

EVOLVE is a randomized, single-blind, non-inferiority clinical
trial that will enroll 291 patients at up to 35 sites in Europe, Australia
and New Zealand. The trial will compare the SYNERGY Stent to the PROMUS
Element Everolimus-Eluting Coronary Stent in patients with a single de novo
native coronary artery lesion. Two drug doses will be evaluated with the
SYNERGY Stent, including an everolimus dose approximately equal to that of
the PROMUS Element Stent and a dose equivalent to half that amount. The
primary clinical endpoint is target lesion failure at 30 days, a composite
measure of cardiac death, myocardial infarction and target lesion
revascularization. The primary angiographic endpoint is in-stent late loss at
six-months as measured by quantitative coronary angiography (QCA). Clinical
follow-up will occur at 30 days, six months, nine months, and every 12 months
out to five years. In addition, all patients will undergo intravascular
ultrasound at the time of initial procedure and at six months. Patient
enrollment in the trial is scheduled to be completed by mid 2011. Data from
the trial will be used to support CE Mark approval for the SYNERGY Stent.

Principal Investigators for the trial are Prof. Meredith and
Stefan Verheye, M.D., Ph.D., Department of Interventional Cardiology,
Middelheim Hospital in Antwerp, Belgium.

"We are pleased to enroll the first patient in the EVOLVE
trial to evaluate this innovative new coronary stent technology," said Prof.
Meredith. "I am enthusiastic about the possibility of having an everolimus
stent that minimizes the initial polymer coating, provides a bare luminal
surface, and becomes a bare-metal stent after a few months once drug delivery
is complete. This type of treatment option could play an important role in
helping reduce adverse events such as late stent thrombosis."

"While some companies are still evaluating their first- or
second-generation drug-eluting stent technology, we are proud to begin
clinical trials on our fourth-generation stent," said Keith Dawkins, M.D.,
Senior Vice President and Chief Medical Officer of Boston Scientific's
Cardiology, Rhythm and Vascular Group. "The SYNERGY Stent is designed to
significantly reduce the amount of polymer and drug to which the vessel wall
is exposed, while eliminating the coating on the inner surface of the stent
where endothelial cell growth is required for healing."

"The SYNERGY Stent is designed to combine the acute
performance advantages of the platinum chromium PROMUS Element Stent with an
innovative bioabsorbable polymer," said Hank Kucheman, Executive Vice
President and President of Boston Scientific's Cardiology, Rhythm and
Vascular Group. "We believe this technology will represent a significant
advance for drug-eluting stents and should help us maintain our global
leadership position in the drug-eluting stent market."

In the U.S., the SYNERGY Stent and the PROMUS Element Stent
are investigational devices and are limited by applicable law to
investigational use only and are not available for sale.

The SYNERGY Stent was previously referred to as the EVOLUTION Stent.

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like "anticipate,"
"expect," "project," "believe," "plan," "estimate," "intend" and similar
words. These forward-looking statements are based on our beliefs, assumptions
and estimates using information available to us at the time and are not
intended to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements regarding
clinical trials, regulatory approvals, competitive offerings, product
performance and our market position. If our underlying assumptions turn out
to be incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections expressed
or implied by our forward-looking statements. These factors, in some cases,
have affected and in the future (together with other factors) could affect
our ability to implement our business strategy and may cause actual results
to differ materially from those contemplated by the statements expressed in
this press release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; intellectual
property; litigation; financial market conditions; and, future business
decisions made by us and our competitors. All of these factors are difficult
or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A -
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A -
Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
hereafter. We disclaim any intention or obligation to publicly update or
revise any forward-looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

    CONTACT: Geraldine Varoqui
    Director International Public Relation
    Tel: +49-2102-489-461
    varoquig@bsci.com

CONTACT: Geraldine Varoqui, Director International Public Relation, Tel: +49-2102-489-461, varoquig at bsci.com